1 Institut de Pharmacologie, Faculté de Médecine, Université Louis Pasteur and 2 Service d'Hypertension, des Maladies Vasculaires et Pharmacologie Clinique, Hôpitaux Universitaires de Strasbourg, 67085 Strasbourg, France
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Renin (RA) and angiotensin-converting enzyme (ACE) activities and angiotensinogen, ANG I, and ANG II levels were measured in the kidney (cortex and medulla) and plasma of Wistar-Kyoto rats on a low-sodium (LS; 0.025% NaCl; n = 8), normal-sodium (NS; 1% NaCl; n = 7), or high-sodium (HS; 8% NaCl; n = 7) diet for 21 days. RA, ANG I, and ANG II levels increased in a manner inversely related to sodium content of the diet in both plasma and renal tissues. The LS diet resulted in a 16-, 2.8-, and 1.8-fold increase in plasma RA, ANG I, and ANG II levels, respectively, compared with those in HS rats. In the renal cortex and medulla, RA, ANG I, and ANG II levels were also increased by diminution of dietary salt content but, in contrast to plasma, ANG II levels increased much more than RA or ANG I levels [5.4 (cortex)- and 4.7 (medulla)-fold compared with HS rats]. In summary, we demonstrated variations of ANG II levels in the kidney during dietary salt modifications. Our results confirm that RA and ACE activity are not the steps limiting intrarenal ANG II levels. Nevertheless, despite RA and ACE activity differences between renal cortex and medulla, ANG I and ANG II levels are equivalent in these two tissues; these results argue against a compartmentalization of RAS in these two intrarenal areas.
kidney; dietary sodium
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays a critical role in the regulation of renal hemodynamics and tubular transport function. Several studies demonstrated that in the kidney, tissue ANG II levels are significantly higher than circulating levels (3, 6, 31). We (10) confirmed these results in the cortex and medulla of rat kidney. Some data also suggest the existence of a differential regulation of circulating and renal angiotensins (2, 6, 9).
The presence of the principal components of the RAS allowing angiotensin formation, angiotensinogen (7, 16, 19), renin (29, 33), and angiotensin-converting enzyme (ACE) (1, 17), has been demonstrated in the kidney. Therefore, intrarenal ANG II levels could result from local synthesis. It should be noted that localization of these components in the kidney differs. Angiotensinogen and renin are mainly located in the renal cortex, whereas ACE activity is fivefold higher in the renal medulla than in the renal cortex (10). These data suggest a different functionality of RAS in renal cortex and medulla.
In plasma, renin activity (RA) is the factor limiting ANG II synthesis, but no clear evidence exists for such a role of this enzyme in the kidney. The objectives of the present study were 1) to determine the factor limiting ANG II levels in the kidney and 2) to explore a different functionality of RAS in the renal cortex and medulla. For this purpose, we applied a physiological approach to get closer to in vivo conditions. Among physiological factors regulating renin secretion, the level of dietary salt intake is of particular relevance because it is well established that synthesis and secretion of renin are inversely related to salt intake (12). We measured RA, ACE activity, angiotensinogen, ANG I, and ANG II in the renal cortex, the renal medulla, and the plasma of rats on a low-sodium (LS), a normal-sodium (NS), or a high-sodium (HS) diet. By measuring the principle components of the RAS simultaneously, we can discuss their respective roles in the key steps of the enzymatic cascade and then determine the factor limiting the RAS in the kidney. By separating the kidney into cortex and medulla, we could investigate a different functionality of RAS in these two tissues, considering the differing localization of angiotensinogen, renin, and ACE as described above.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Experimental Design
Male Wistar-Kyoto rats were obtained from Iffa-Credo (l'Arbresle, France) and housed in our laboratory 1 wk before the beginning of the treatments. A 12:12-h dark-light cycle was used (lights on from 6 AM to 6 PM). Animals had free access to tap water and consumed a diet of rat chow (UAR, Epinay sur Orge, France). For the experiments with an altered dietary salt intake, the animals were fed a low-salt (LS group, 0.025% NaCl; n = 8), a normal-salt (NS group, 1% NaCl; n = 7), or a high-salt (HS group, 8% NaCl; n = 7) diet for 21 days. The different salt diets (UAR 212, UAR 210, and UAR 210+, respectively) and distilled drinking water were available ad libitum. All animals were 10 wk old on the day of sampling and were deprived of food but not of water the night before plasma and tissue sampling. Because anesthesia induces a strong stimulation of RAS, rats were killed by decapitation.Plasma and Kidney Sampling
After decapitation, ~5 ml of trunk blood were rapidly collected into ice-cold tubes containing 0.25 ml of inhibitor cocktail [2.5 mM phenanthroline, 3 mM EDTA, 0.1 mM pepstatin, 3 µM rat renin inhibitor Ac-His-Pro-Phe-Val-Sta-Leu-Phe-NH2 (Néosystem), 0.11 mM neomycin sulfate; final concentrations] for measurement of ANG I and ANG II, 1 ml was used for plasma renin activity (PRA) and plasma angiotensinogen (EDTA tube), and 1 ml was used for ACE activity (lithium heparin tube). The blood was immediately centrifuged at 4°C for 10 min at 2,000 g. Plasma samples were frozen in liquid nitrogen and stored atAfter decapitation, kidneys were immediately removed and bisected. Each
half of the right kidney was rapidly dissected on an ice-cold plate
into cortex and medulla. Meticulous care was taken to cut fine strips
of the outer cortex and to restrict the medulla to its internal section
to limit the presence of juxtamedullar glomerules. One-half of each
tissue sample was used for measurement of ANG I and ANG II; these were
weighed and subsequently homogenized in ice-cold methanol
(9). The homogenates were centrifuged at 4°C for 10 min
at 2,000 g, and the supernatants were evaporated to dryness
and stored at 80°C. The other half of each tissue sample was used
for determination of renal RA and was homogenized in a phosphate buffer
with 144 mM PMSF-10 mM phenylmercuric acetate (in ethanol) and
centrifuged at 4°C for 20 min at 5,000 g (6). The supernatants were stored at
20°C until assay.
Each half of the left kidney was also dissected into cortex and medulla
and weighed. One-half of each tissue sample was used for determination
of renal angiotensinogen and homogenized in a phosphate buffer with 1.5 M ammonium sulfate, 1.5 mM pepstatin (in ethanol), and 144 mM PMSF-10
mM phenylmercuric acetate (in ethanol); the homogenate was centrifuged
at 4°C for 20 min at 5,000 g, and the supernatant was
decanted. To precipitate angiotensinogen, the ammonium sulfate
concentration was adjusted to 2.5 M by addition of 4 M ammonium sulfate
and the supernatant was centrifuged as before. The ammonium sulfate
precipitate was resuspended in water and stored at 20°C until assay
(6). The other half of each tissue sample was frozen in
liquid nitrogen; after thawing of the cortex and the medulla, Triton
X-100 (0.3%) was added and the tissues were homogenized and
centrifuged at 4°C for 20 min at 11,500 g after
sonication. The supernatants were diluted in Triton X-100 for
determination of ACE activity and stored at
20°C until assay.
Measurement of RAS Components
Plasma and renal angiotensinogen. Plasma angiotensinogen was determined by incubating diluted plasma with a phosphate buffer, a pool of exogenous rat renin, and 144 mM PMSF (in ethanol) (6). After incubation at 37°C for 60 min, ANG I generation was quantified by RIA as described below. Cortical and medullar angiotensinogen samples were incubated with a phosphate buffer, a pool of exogenous rat renin, and 144 mM PMSF-10 mM phenylmercuric acetate (in ethanol). After incubation at 37°C for 120 min, 0.5 ml of 1% trifluoroacetic acid was added; each incubation was extracted with a Sep-Pak C18 cartridge (Oasis Waters, Milford, Ma), the eluate was evaporated to dryness, and ANG I was determined by RIA (6). Plasma and renal angiotensinogen are expressed as nanograms of ANG I generated per milliliter of plasma and nanograms of ANG I generated per gram of tissue weight, respectively.
Plasma and renal tissue renin activities. PRA was measured by determining the level of ANG I generated during a 30-min incubation of plasma at 37°C in the presence of 5 mM 8-hydroxyquinoline. ANG I was measured by RIA. In the cortex and the medulla, RA was measured after determination of ANG I generated during a 30-min incubation of diluted supernatants in the presence of plasma enriched in angiotensinogen obtained from rats 48 h after binephrectomy (6). ANG I was measured by RIA. PRA and renal RA are expressed as nanograms of ANG I generated per milliliter of plasma per hour and micrograms of ANG I generated per gram of tissue weight per hour, respectively.
Plasma and renal ACE activities. ACE activity was determined in vitro with an enzymatic method. In vitro plasma and renal ACE activities were determined as described by Unger et al. (35) in the presence of an artificial substrate (10 mM N-carbobenzoxy-Phe-His-Leu, 67 mM phosphate buffer, pH 8.0, 300 mM NaCl, 10 µM ZnSO4). The dipeptide (His-Leu) produced by the reaction was measured spectrofluorimetrically after coupling with o-phthaldialdehyde. To ensure linearity of the ACE activity measurement, the protein concentration in the assay was maintained at <2 mg/ml (cortex or medulla) or <20 mg/ml (plasma) (36). ACE activity is expressed as nanomoles of His-Leu formation per minute per milligram of protein.
Plasma and renal angiotensins. Plasma angiotensins were extracted by reversible adsorption to phenylsilyl-silica (Bondelut-PH; Analytichem, Harbor City, CA), and ANG II was additionally separated from other peptides by isocratic reversed-phase HPLC (Nucleosyl 100-5C; Macherey-Nagel, Oensingen, Switzerland) according to the method of Nussberger et al. (26). ANG I and ANG II levels were quantified by RIA with rabbit anti-ANG I and anti-ANG II sera. Antibodies to ANG I and ANG II were raised in our laboratory in rabbits immunized against the peptide coupled to BSA by carbodiimide condensation (21). Renal angiotensins were determined with slight modifications of the method described by Fox et al. (9). Briefly, the dried residues were dissolved in a phosphate buffer containing 267 mg/l BSA. Renal angiotensins were extracted by reversible adsorption to phenylsilyl-silica (Bondelut-PH) and quantified by RIA with rabbit anti-ANG I and anti-ANG II sera. Results are reported in femtomoles per milliliter of plasma or in femtomoles per gram of tissue weight.
We verified that blood contamination did not contribute to our measurements of renal RAS components. For this purpose, we compared the renal cortex and medulla RAS (RA, ACE activity, ANG I and ANG II levels) of rats whose kidneys were rinsed or not with physiological serum (data not shown). Renal cortex and medulla were dissected in the same conditions as described in Plasma and Kidney Sampling. The results showed that there was no difference between the cortex and medulla of kidneys rinsed or not for all the measured components of the RAS. Thus blood contamination does not seem to play a significant part in renal RAS.Statistical Analysis
Data are means ± SE. For each parameter, control and treated groups were compared with a one-way ANOVA followed by Tukey's multiple-comparison test (SIGMA STAT; SPSS, Chicago, IL). Differences were considered statistically significant at P < 0.05 levels. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effects of Dietary Salt Changes on Different Components of RAS in Plasma
The LS diet led to a decrease in plasma angiotensinogen levels compared with control (NS) diet (843.31 ± 41.48 vs. 990.50 ± 35.64 ng ANG I/ml; P < 0.05) and to a marked increase in PRA (97.87 ± 6.22 vs. 21.82 ± 1.21 ng ANG I · ml
|
The HS diet did not significantly change plasma angiotensinogen levels,
ANG I and ANG II levels, or the ANG II-to-ANG I ratio compared with the
NS diet (Fig. 1). The HS diet decreased PRA (6.16 ± 1.28 vs.
21.82 ± 1.21 ng ANG
I · ml1 · h
1;
P < 0.001) and increased ACE activity (5.71 ± 0.14 vs. 4.87 ± 0.25 nmol
His-Leu · min
1 · mg
protein
1; P < 0.01) compared with the NS diet.
Effects of Dietary Salt Changes on Different Components of RAS in Renal Cortex
The LS diet led to a decrease in cortical angiotensinogen levels (101.82 ± 7.74 vs. 156.70 ± 14.68 ng ANG I/g tissue; P < 0.05) and increased cortical RA (363.25 ± 28.08 vs. 184.47 ± 6.81 µg ANG I · g tissue
|
The HS diet did not change cortical angiotensinogen levels, RA, the ANG II-to-ANG I ratio, or ACE activity compared with the NS diet. The HS diet decreased ANG I (196.92 ± 22.26 vs. 317.53 ± 16.99 fmol/g tissue; P < 0.01) and ANG II (151.24 ± 21.28 vs. 306.58 ± 25.08 fmol/g tissue; P < 0.001) levels compared with the NS diet (Fig. 2).
Effects of Dietary Salt Changes on Different Components of RAS in Renal Medulla
Salt restriction led to a decrease in medullar angiotensinogen levels (87.87 ± 6.26 vs. 134.41 ± 6.78 ng ANG I/g tissue; P < 0.001) and increased medullary RA (151.84 ± 6.62 vs. 58.02 ± 2.71 µg ANG I · g tissue
|
The HS diet did not change medullary angiotensinogen levels, the ANG
II-to-ANG I ratio, or ACE activity compared with the NS diet. The HS
diet decreased RA (27.30 ± 2.63 vs. 58.02 ± 2.71 µg ANG
I · g tissue1 · h
1;
P < 0.001), ANG I levels (224.05 ± 6.87 vs.
325.96 ± 22.32 fmol/g tissue; P < 0.001), and
ANG II levels (182.66 ± 20.80 vs. 345.86 ± 23.83 fmol/g
tissue; P < 0.05) compared with the NS diet (Fig. 3).
The differences observed in LS rats compared with NS rats were similar but amplified compared with HS rats for the complete RAS in plasma, renal cortex, and renal medulla.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the present study, we analyzed the variation of the different components of the RAS in kidney and plasma of rats subjected to RA changes induced by high- or low-salt intake. Our findings confirm that ANG II levels are high in kidney compared with plasma in relation to changes in dietary salt intake.
As expected, PRA was stimulated by salt restriction and decreased by salt excess. The magnitude of changes of PRA observed after salt restriction is in agreement with prior reports (14, 22, 28). This increase in PRA could result from a decrease in tubular sodium in the macula densa, resulting in a release of renin from juxtaglomerular cells (22). With an 8% NaCl diet, we expected a suppression of PRA as shown by Nishimura et al. (25), but our results did not confirm this. Salt restriction also leads to a decrease in plasma angiotensinogen levels, which can be explained by marked elevation of circulating renin and/or by modifications of angiotensinogen synthesis and secretion from the liver (22). Several studies showed that a low salt intake did not influence the expression of hepatic angiotensinogen mRNA (18, 27). We suggest that the decrease in angiotensinogen levels induced by salt restriction observed in the plasma could be due to a higher consumption of angiotensinogen by the elevated plasma renin. Some authors found much higher ANG I levels than measured in the present study (2, 9). This was probably due to a failure to completely inhibit renin during plasma sample processing, which may result in artifactually high levels of ANG I. In our study, we used pepstatin and a renin inhibitor as used by Campbell et al. (4-6) to limit this phenomenon. Three weeks of salt restriction were associated with an elevation of plasma ANG I and ANG II levels. This elevation followed the marked increase in PRA. Plasma ACE activity was slightly modified by dietary salt changes but did not seem to play a limiting role in ANG II synthesis because the plasma ANG II-to-ANG I ratio was not affected. Therefore, we confirm that plasma ACE activity is not the limiting factor for circulating ANG II levels. Together, our findings confirm that renin is the limiting factor of ANG I and ANG II synthesis in the plasma.
RA in the cortex increased in LS and decreased in HS animals as in plasma; these results confirm other studies (9, 15). Sodium deprivation does not induce parallel increases in plasma renin levels and renin biosynthesis as shown by a previous report (24). In fact, an increase in renal RA is merely due to higher synthesis and storage whereas an increase in PRA reflects a release of renin. The high levels of ANG I in the renal cortex compared with those in the plasma suggest that renal tissue ANG I is not due to a simple contamination from plasma but may be due to a local synthesis. Nevertheless, despite high cortical RA induced by salt restriction, ANG I levels were relatively weak. It should be noted that the RA we measured in the kidney is the combination of renin stocked in vesicles and free renin that is only available to act on angiotensinogen. We also suggest that angiotensinogen could be a limiting factor for ANG I synthesis through its low quantity available in the kidney; indeed, cortical angiotensinogen levels were sixfold lower than those measured in the plasma. On the other hand, ANG I synthesis requires the colocalization of angiotensinogen and renin; renin is mainly located in the juxtaglomerular apparatus into vesicles despite the findings of Henrich et al. (13) and Moe et al. (23) that cultured proximal tubule cells produce renin in small quantities and contain renin mRNA. Most intrarenal angiotensinogen mRNA and protein have been located in proximal tubule cells (7, 16, 18). Thus angiotensinogen and renin are colocalized in limited renal areas such as lymph or proximal tubules. Therefore, independently from renin and angiotensinogen quantities, their colocalization could limit renal ANG I synthesis. During dietary sodium changes, a similar pattern was observed for angiotensinogen levels in the cortex compared with the plasma. This contrasts with data showing that in the liver sodium deprivation stimulated and sodium excess decreased renal angiotensinogen mRNA expression (18, 20, 32). Therefore, we suggest that the decrease in cortical angiotensinogen induced by sodium restriction may reflect its extensive consumption by high renin levels. Concerning ANG II levels in control rats, we observed threefold higher levels in the cortex than in the plasma, which probably excludes plasma contamination. Cortical ANG II levels increased in the same way as ANG I, which could suggest an intrarenal synthesis. However, during sodium restriction, ANG II levels increased much more than ANG I levels: 2.7-fold for ANG II vs. 1.6-fold for ANG I compared with the control diet. This led to an increase in the ANG II-to-ANG I ratio that could not be explained by an increase in ACE activity, which was not modified. Of course, we cannot exclude an ACE-independent way to produce ANG II; nevertheless, studies using ANG II perfusions showed that a significant part of intrarenal ANG II resulted from the uptake of circulating and/or intrarenal produced ANG II via the internalization of AT1 receptors (37, 38, 39). Therefore, we suggest that the strong increase in ANG II levels we observed in the cortex during low-salt intake could be due, in part, to the uptake phenomenon that would occur here under more physiological conditions than during ANG II infusion.
In the medulla, we observed different amounts of RA and ACE activity compared with the renal cortex. RA of control rats was threefold lower than that observed in the cortex. Because the presence of renin is highly localized in the juxtaglomerular apparatus located in the cortex, one can wonder about the origin of renin in the medulla. Renin can reach the medulla via microcirculation or lymphatics (8). Renin has also been described in pinocytotic vacuoles in the proximal straight tubule and the connecting tubules (11). Recent data demonstrate specific binding sites for renin in the medulla, which have the capacity to bind renin threefold lower than in the cortex (30). Finally, renin could also result from a local synthesis in the medulla; in fact, studies using Northern blot analysis demonstrated the presence of renin mRNA in the medulla but in low quantity (18); these studies also showed that RA was influenced by dietary salt changes. To our knowledge, no angiotensinogen levels have been reported in the rat kidney medulla; they were equivalent to those found in the cortex. These results were rather unexpected because angiotensinogen mRNA is mainly located in proximal tubules (19) whereas the presence of small amounts of angiotensinogen mRNA were described in glomerules and vasa recta (34). ANG II contents were equivalent in the cortex and medulla despite a fivefold higher ACE activity and threefold lower RA in the medulla, suggesting that ACE and RA are not the steps limiting ANG II levels. We found similar responses for all parameters of the RAS in the renal medulla compared with those found in the cortex during dietary salt changes. Thus, despite a different localization of angiotensinogen, renin, and ACE in the renal cortex and medulla, ANG I and ANG II levels in these two tissues are equivalent and respond in a similar trend to altered sodium intake; these results suggest a similar functionality in these two anatomic parts of the kidney.
In summary, our results confirm that neither RA nor ACE activity is a factor limiting ANG II levels in the kidney. We propose that the factor limiting renal ANG II levels could be angiotensinogen through its low quantity available in the kidney or through its colocalization with renin restricted to limited renal areas. Nevertheless, we could not provide clear evidence for the existence of a compartmentalization of the RAS in the kidney: indeed, despite RA and ACE activity differences between renal cortex and medulla, ANG I and ANG II levels are equivalent in both tissues and respond in a similar trend to dietary salt intake. These results argue against a compartmentalization of the RAS in the renal cortex and medulla. Surprisingly, during sodium restriction, intrarenal ANG II levels increased more than ANG I levels. We suggest that renal ANG II levels result not solely from a local synthesis of ANG I but also from an uptake of circulating and/or intrarenally produced ANG II via AT1 receptors; this should be confirmed by complementary experiences with an AT1 receptor antagonist.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: M. Grima, Institut de Pharmacologie, Faculté de Médecine, 11, rue Humann, 67085 Strasbourg Cedex, France (E-mail: Michele.Grima{at}pharmacoulp.u-strasbg.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
July 2, 2002;10.1152/ajprenal.00321.2001
Received 26 October 2001; accepted in final form 25 June 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alhenc-Gelas, F,
Baussant T,
Hubert C,
Soubrier F,
and
Corvol P.
The angiotensin converting enzyme in the kidney.
J Hypertens
7:
S9-S14,
1989.
2.
Allan, DR,
McKnight JA,
Kifor I,
Coletti CM,
and
Hollenberg NK.
Converting enzyme inhibition and renal tissue angiotensin II in the rat.
Hypertension
24:
516-522,
1994[Abstract].
3.
Braam, B,
Mitchell KD,
Fox J,
and
Navar LG.
Proximal tubular secretion of angiotensin II in rats.
Am J Physiol Renal Fluid Electrolyte Physiol
264:
F891-F898,
1993
4.
Campbell, DJ.
Differential regulation of angiotensin peptides in plasma and kidney: effects of adrenalectomy and estrogen treatment.
Clin Exp Hypertens
19:
687-698,
1997[ISI][Medline].
5.
Campbell, DJ,
Kladis A,
and
Duncan AM.
Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.
Hypertension
23:
439-449,
1994[Abstract].
6.
Campbell, DJ,
Lawrence AC,
Towrie A,
Kladis A,
and
Valentijn AJ.
Differential regulation of angiotensin peptide levels in plasma and kidney of the rat.
Hypertension
18:
763-773,
1991[Abstract].
7.
Darby, IA,
Congiu M,
Fernley RT,
Sernia C,
and
Coghlan JP.
Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney.
Kidney Int
46:
1557-1560,
1994[ISI][Medline].
8.
Dzau, VJ,
Wilcox CS,
Sands K,
and
Dunckel P.
Dog inactive renin: biochemical characterization and secretion into renal plasma and lymph.
Am J Physiol Endocrinol Metab
250:
E55-E61,
1986
9.
Fox, J,
Guan S,
Hymel AA,
and
Navar LG.
Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats.
Am J Physiol Renal Fluid Electrolyte Physiol
262:
F902-F909,
1992
10.
Grima, M,
Ingert C,
Michel B,
Barthelmebs M,
and
Imbs JL.
Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat.
Clin Exp Hypertens
19:
671-685,
1997[ISI][Medline].
11.
Hackenthal, E,
Metz R,
Buhrle CP,
and
Taugner R.
Intrarenal and intracellular distribution of renin and angiotensin.
Kidney Int
31:
S4-S17,
1987[ISI].
12.
Hackenthal, E,
Paul M,
Ganten D,
and
Taugner R.
Morphology, physiology, and molecular biology of renin secretion.
Physiol Rev
70:
1067-1116,
1990
13.
Henrich, WL,
McAllister EA,
Eskue A,
Miller T,
and
Moe OW.
Renin regulation in cultured proximal tubular cells.
Hypertension
27:
1337-1340,
1996
14.
Herrmann, HC,
and
Dzau VJ.
The feedback regulation of angiotensinogen production by components of the renin-angiotensin system.
Circ Res
52:
328-334,
1983[Abstract].
15.
Holmer, S,
Eckardt KU,
LeHir M,
Schricker K,
Riegger G,
and
Kurtz A.
Influence of dietary NaCl intake on renin gene expression in the kidneys and adrenal glands of rats.
Pflügers Arch
425:
62-67,
1993[ISI][Medline].
16.
Hunt, MK,
Ramos SP,
Geary KM,
Norling LL,
Peach MJ,
Gomez RA,
and
Carey RM.
Colocalization and release of angiotensin and renin in renal cortical cells.
Am J Physiol Renal Fluid Electrolyte Physiol
263:
F363-F373,
1992
17.
Ikemoto, F,
Song GB,
Tominaga M,
Kanayama Y,
and
Yamamoto K.
Angiotensin converting enzyme predominates in the inner cortex and medulla of the rat kidney.
Biochem Biophys Res Commun
144:
915-921,
1987[ISI][Medline].
18.
Ingelfinger, JR,
Pratt RE,
Ellison K,
and
Dzau VJ.
Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla.
J Clin Invest
78:
1311-1315,
1986[ISI][Medline].
19.
Ingelfinger, JR,
Zuo WM,
Fon EA,
Ellison KE,
and
Dzau VJ.
In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system.
J Clin Invest
85:
417-423,
1990[ISI][Medline].
20.
Jo, H,
Yang EK,
Lee WJ,
Park KY,
Kim HJ,
and
Park JS.
Gene expression of central and peripheral renin-angiotensin system components upon dietary sodium intake in rats.
Regul Pept
67:
115-121,
1996[ISI][Medline].
21.
Menard, J,
and
Catt KJ.
Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I.
Endocrinology
90:
422-430,
1972[ISI][Medline].
22.
Michel, JB,
Arnal JF,
Cohen-Solal A,
Denolle T,
and
Drouin P.
Médecine Cardiovasculaire du Système Rénine-Angiotensine. Paris: Pradel, 1992, p. 85-104.
23.
Moe, OW,
Ujiie K,
Star RA,
Miller RT,
Widell J,
Alpern RJ,
and
Henrich WL.
Renin expression in renal proximal tubules.
J Clin Invest
91:
774-779,
1993[ISI][Medline].
24.
Nakamura, N,
Soubrier F,
Menard J,
Panthier JJ,
Rougeon F,
and
Corvol P.
Nonproportional changes in plasma renin concentration, renal renin content, and rat renin messenger RNA.
Hypertension
7:
855-859,
1985[Abstract].
25.
Nishimura, M,
Nanbu A,
Ohtsuka K,
Takahashi H,
Iwai N,
Kinishita M,
and
Yoshimura M.
Sodium intake regulates renin gene expression differently in the hypothalamus and kidney of rats.
J Hypertens
15:
509-516,
1997[ISI][Medline].
26.
Nussberger, J,
Brunner DB,
Waeber B,
and
Brunner HR.
Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma.
Hypertension
8:
476-482,
1986[Abstract].
27.
Pratt, RE,
Zou WM,
Naftilan AJ,
Ingelfinger JR,
and
Dzau VJ.
Altered sodium regulation of renal angiotensinogen mRNA in the spontaneously hypertensive rat.
Am J Physiol Renal Fluid Electrolyte Physiol
256:
F469-F474,
1989
28.
Schricker, K,
Holmer S,
Kramer BK,
Riegger GA,
and
Kurtz A.
The role of angiotensin II in the feedback control of renin gene expression.
Pflügers Arch
434:
166-172,
1997[ISI][Medline].
29.
Schunkert, H,
Ingelfinger JR,
and
Dzau VJ.
Evolving concepts of the intrarenal renin-angiotensin system in health and disease: contributions of molecular biology.
Renal Physiol Biochem
14:
146-154,
1991[ISI][Medline].
30.
Sealey, JE,
Catanzaro DF,
Lavin TN,
Gahnem F,
Pitarresi T,
Hu LF,
and
Laragh JH.
Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site.
Am J Hypertens
9:
491-502,
1996[ISI][Medline].
31.
Seikaly, MG,
Arant BS, Jr,
and
Seney FD, Jr.
Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat.
J Clin Invest
86:
1352-1357,
1990[ISI][Medline].
32.
Singh, I,
Grams M,
Wang WH,
Yang T,
Killen P,
Smart A,
Schnermann J,
and
Briggs JP.
Coordinate regulation of renal expression of nitric oxide synthase, renin, and angiotensinogen mRNA by dietary salt.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F1027-F1037,
1996
33.
Taugner, R,
Buhrle CP,
Ganten D,
Hackenthal E,
Hardegg C,
Hardegg G,
and
Nobiling R.
Immunohistochemistry of the renin-angiotensin-system in the kidney.
Clin Exp Hypertens A
5:
1163-1177,
1983[ISI][Medline].
34.
Terada, Y,
Tomita K,
Nonoguchi H,
and
Marumo F.
PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney.
Kidney Int
43:
1251-1259,
1993[ISI][Medline].
35.
Unger, T,
Schull B,
Rascher W,
Lang RE,
and
Ganten D.
Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat.
Biochem Pharmacol
31:
3063-3070,
1982[ISI][Medline].
36.
Welsch, C,
Grima M,
Giesen EM,
Helwig JJ,
Barthelmebs M,
Coquard C,
and
Imbs JL.
Assay of tissue angiotensin converting enzyme.
J Cardiovasc Pharmacol
14:
S26-S31,
1989[ISI][Medline].
37.
Zou, LX,
Hymel A,
Imig JD,
and
Navar LG.
Renal accumulation of circulating angiotensin II in angiotensin II-infused rats.
Hypertension
27:
658-662,
1996
38.
Zou, LX,
Imig JD,
Hymel A,
and
Navar LG.
Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor.
Am J Hypertens
11:
570-578,
1998[ISI][Medline].
39.
Zou, LX,
Imig JD,
Von Thun AM,
Hymel A,
Ono H,
and
Navar LG.
Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats.
Hypertension
28:
669-677,
1996